JP5406827B2 - （チオ）カルバモイル−シクロヘキサン誘導体の代謝物 - Google Patents

（チオ）カルバモイル−シクロヘキサン誘導体の代謝物 Download PDF

Info

Publication number
JP5406827B2
JP5406827B2 JP2010508911A JP2010508911A JP5406827B2 JP 5406827 B2 JP5406827 B2 JP 5406827B2 JP 2010508911 A JP2010508911 A JP 2010508911A JP 2010508911 A JP2010508911 A JP 2010508911A JP 5406827 B2 JP5406827 B2 JP 5406827B2
Authority
JP
Japan
Prior art keywords
dopamine
compound
optionally substituted
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010508911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527983A5 (OSRAM
JP2010527983A (ja
Inventor
エーヴァ・アーガイネー・チョンゴル
ノルベルト・アンタル・キルシュネル
エーヴァ・シュミット
イシュトヴァーン・ジェルティアーン
ベーラ・キス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2010527983A publication Critical patent/JP2010527983A/ja
Publication of JP2010527983A5 publication Critical patent/JP2010527983A5/ja
Application granted granted Critical
Publication of JP5406827B2 publication Critical patent/JP5406827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010508911A 2007-05-18 2008-05-15 （チオ）カルバモイル−シクロヘキサン誘導体の代謝物 Active JP5406827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP0700353 2007-05-18
HU0700353A HUP0700353A2 (en) 2007-05-18 2007-05-18 Metabolites of (thio)carbamoyl-cyclohexane derivatives
PCT/HU2008/000046 WO2008142461A1 (en) 2007-05-18 2008-05-15 Metabolites of (thio)carbamoyl-cyclohexane derivatives

Publications (3)

Publication Number Publication Date
JP2010527983A JP2010527983A (ja) 2010-08-19
JP2010527983A5 JP2010527983A5 (OSRAM) 2011-07-07
JP5406827B2 true JP5406827B2 (ja) 2014-02-05

Family

ID=89987527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508911A Active JP5406827B2 (ja) 2007-05-18 2008-05-15 （チオ）カルバモイル−シクロヘキサン誘導体の代謝物

Country Status (24)

Country Link
US (1) US8765765B2 (OSRAM)
EP (1) EP2155707B1 (OSRAM)
JP (1) JP5406827B2 (OSRAM)
CN (1) CN101679330A (OSRAM)
AP (1) AP2009005011A0 (OSRAM)
AU (1) AU2008252619A1 (OSRAM)
BR (1) BRPI0811744A2 (OSRAM)
CA (1) CA2684149C (OSRAM)
CO (1) CO6251252A2 (OSRAM)
CU (1) CU23852B1 (OSRAM)
EA (1) EA200971069A1 (OSRAM)
EC (1) ECSP099819A (OSRAM)
GE (1) GEP20125523B (OSRAM)
HU (1) HUP0700353A2 (OSRAM)
IL (1) IL201534A0 (OSRAM)
MA (1) MA31432B1 (OSRAM)
MX (1) MX2009012371A (OSRAM)
MY (1) MY150784A (OSRAM)
NI (1) NI200900202A (OSRAM)
NZ (1) NZ580646A (OSRAM)
TN (1) TN2009000459A1 (OSRAM)
TW (1) TW201002324A (OSRAM)
WO (1) WO2008142461A1 (OSRAM)
ZA (1) ZA200907425B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
WO2009104739A1 (ja) * 2008-02-21 2009-08-27 田辺三菱製薬株式会社 経口投与用固形製剤
UA104869C2 (uk) 2008-07-16 2014-03-25 Ріхтер Гедеон Нірт. Фармацевтичні композиції, що містять ліганди рецептора дофаміну
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
ES2447295T3 (es) * 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
WO2011060363A2 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
HUP0900790A2 (en) * 2009-12-17 2011-09-28 Richter Gedeon Nyrt A new process for the preparation of piperazine and their hydrochloric salts
WO2014031162A1 (en) * 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018153297A1 (zh) * 2017-02-24 2018-08-30 深圳市灵兰生物医药科技有限公司 新型多巴胺d3受体选择性配体及其制备方法和医药应用
CN108586389B (zh) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 一种合成卡利拉嗪的方法
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CN112239433B (zh) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
TW202118758A (zh) * 2019-11-05 2021-05-16 大陸商上海翰森生物醫藥科技有限公司 苯并噻吩類衍生物調節劑、其製備方法和應用
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666911A (en) 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
US4880797A (en) 1986-03-20 1989-11-14 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives and antibacterial agents
JPH01199977A (ja) 1987-11-16 1989-08-11 Mochida Pharmaceut Co Ltd セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物
GB8802622D0 (en) 1988-02-05 1988-03-02 Glaxo Group Ltd Chemical compound
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
JPH04275280A (ja) 1991-03-04 1992-09-30 Nippon Chem Ind Co Ltd ４ｈ−２，３−ジヒドロ−２−イミノ−１，３−ベンゾチアジン−４−オン類の製造方法
JPH0532586A (ja) 1991-07-26 1993-02-09 Mitsubishi Petrochem Co Ltd ２，６−ナフタレンジカルボン酸の製造方法
JPH05310745A (ja) 1992-05-13 1993-11-22 Takeda Chem Ind Ltd ジエラジラクトンおよび抗炎症剤
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
RU2230740C2 (ru) 1998-03-31 2004-06-20 Акадиа Фармасьютикалз, Инк. Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
KR20010053010A (ko) 1998-06-30 2001-06-25 이베 사치아키 엔-페닐-엔'-페닐프로필피페라진 유도체 및 그의제조방법
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
BR0207832A (pt) 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
DE102004047517A1 (de) 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
HUP0500170A3 (en) 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUE033357T2 (en) 2007-05-11 2017-11-28 Richter Gedeon Nyrt Crystalline form of carbamoylcyclohexane derivatives
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700370A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
US20100256145A1 (en) 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
WO2009104739A1 (ja) 2008-02-21 2009-08-27 田辺三菱製薬株式会社 経口投与用固形製剤
UA104869C2 (uk) 2008-07-16 2014-03-25 Ріхтер Гедеон Нірт. Фармацевтичні композиції, що містять ліганди рецептора дофаміну
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts

Also Published As

Publication number Publication date
NZ580646A (en) 2012-03-30
EA200971069A1 (ru) 2010-04-30
EP2155707B1 (en) 2013-03-13
HU0700353D0 (en) 2007-07-30
TW201002324A (en) 2010-01-16
GEP20125523B (en) 2012-05-25
BRPI0811744A2 (pt) 2014-11-11
CN101679330A (zh) 2010-03-24
TN2009000459A1 (en) 2011-03-31
JP2010527983A (ja) 2010-08-19
ECSP099819A (es) 2010-03-31
CU23852B1 (es) 2012-10-15
CA2684149C (en) 2012-12-04
MY150784A (en) 2014-02-28
MX2009012371A (es) 2009-12-03
MA31432B1 (fr) 2010-06-01
US8765765B2 (en) 2014-07-01
NI200900202A (es) 2010-03-11
CU20090196A7 (es) 2011-07-11
AP2009005011A0 (en) 2009-10-31
CO6251252A2 (es) 2011-02-21
WO2008142461A1 (en) 2008-11-27
EP2155707A1 (en) 2010-02-24
HUP0700353A2 (en) 2008-12-29
US20100137335A1 (en) 2010-06-03
ZA200907425B (en) 2010-07-28
AU2008252619A1 (en) 2008-11-27
CA2684149A1 (en) 2008-11-27
IL201534A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
JP5406827B2 (ja) （チオ）カルバモイル−シクロヘキサン誘導体の代謝物
DE60225162T2 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
US7705003B2 (en) Cyclohexylamides as dopamine D3, D2 and 5-HT1A Antagonists
DE602004006431T2 (de) Derivate von n-äheteroaryl(piperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
DE60120077T2 (de) Modulatoren des Glucocorticoid-Rezeptors
DE69529418T2 (de) Cyclopropachromencarbonsäure derivate
KR102615099B1 (ko) 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
HUP0401086A2 (hu) 4-[(Fenil-piperazinil)-metil]-benzamid-származékok és alkalmazásuk fájdalom, szorongás vagy gasztrointesztinális zavarok kezelésére szolgáló gyógyszerkészítmények előállítására és eljárás a vegyületek előállítására
SK188399A3 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
KR102615095B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 효능제
FI101301B (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahyd roatsepiinijohdannaisten valmistamiseksi
EP3204374B1 (en) Isoindoline derivatives
KR20130002316A (ko) 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태
US4778789A (en) Piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
DE60130691T2 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
MXPA02003673A (es) Uso de derviados carbonilamino contra alteraciones del sistema nervioso central.
US7592360B2 (en) 3-fluoro-piperidines as NMDA/NR2B antagonists
DE69115954T2 (de) Kondensierte 7-gliedrige zyklische Verbindungen und diese enthaltende antipsychotische Zubereitung
DE602005006018T2 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
JPH037280A (ja) 新規ベンゾチオピラニルアミン
KR20100028021A (ko) (티오)카르바모일-시클로헥산 유도체의 대사물질
EP1841752B1 (en) 3,4-dihydro-2-naphthamide derivatives and their therapeutic applications
DE60102471T2 (de) Indolderivate zur verwendung in der behandlung von zns-störungen
HK1140474A (en) Metabolites of (thio) carbamoyl-cyclohexane derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131101

R150 Certificate of patent or registration of utility model

Ref document number: 5406827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250